NCT03073044 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Ringendahl H, Werheid K, Leplow B, Ellgring H, Annecke R, Emmans D
[Recommendations for standarsized psychological diagnosis in Parkinson patients]. Nervenarzt. 2000 Dec;71(12):946-54. Review. German.
Spliethoff-Kamminga NG, Zwinderman AH, Springer MP, Roos RA
Psychosocial problems in Parkinson's disease: evaluation of a disease-specific questionnaire. Mov Disord. 2003 May;18(5):503-9.

Italian Validation of the Belastungfragebogen Parkinson Kurzversion (BELA-P-K): a Disease-specific Questionnaire for Evaluation of the Subjective Perception of Quality of Life.

Details for clinical trial NCT03073044

Clinical trial NCT03073044 - References